Supernus’ Qelbree (SPN-812) Receives the US FDA’s Approval for the Treatment of ADHD

 Supernus’ Qelbree (SPN-812) Receives the US FDA’s Approval for the Treatment of ADHD

Shots:

  • The approval is based on data from an extensive development program that consists of four P-III clinical trials evaluating Qelbree in 1000+ pediatric patients aged 6 to 17 yrs. with ADHD
  • The program demonstrated the proven efficacy and a tolerable safety profile. In Dec’2020, the company reported the results from the P- III trial for Qelbree and plans to submit an sNDA to the FDA in H2’21
  • Qelbree is the first novel non-stimulant treatment for ADHD. The company plans to make it available in the US in Q2’21

Click here ­to­ read full press release/ article | Ref: Globalnewswire | Image: Supernus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post